In the latest effort to find some common ground between the neutral MITRA-FR trial and the positive COAPT study, investigators for the former have reanalyzed patients according to baseline severity of ...

Patients treated with the MitraClip (Abbott) at one of three European hospitals were more likely to survive and avoid rehospitalization if they fit a “COAPT-like profile” based on echocardiography ...

Chicago, IL—Real-world patients with mitral regurgitation (MR) not meeting the COAPT eligibility criteria who ultimately underwent clip-based transcatheter mitral valve repair fared just as well as ...

NEW ORLEANS, LA—A detailed look at the echocardiographic results from the COAPT trial has failed to pinpoint any baseline echocardiographic factors that could help valve teams decide which patients ...

NEW ORLEANS — An echocardiographic substudy of the COAPT trial failed to identify any baseline echo characteristics to differentiate patients with heart failure (HF) and secondary mitral regurgitation ...

NEW YORK, NY—More postmarket registry data confirm the safety and efficacy of mitral transcatheter edge-to-edge repair (M-TEER) with MitraClip (Abbott) in patients with secondary mitral regurgitation ...

Fewer than one in five patients enrolled in the COAPT trial of the MitraClip (Abbott) were “super-responders” to their assigned therapies, with more seen in the percutaneous intervention group than in ...

One-year mortality rates for patients with secondary mitral regurgitation (MR) treated with the next-generation MitraClip NTR and XTR systems (Abbott) as part of the real-world, global EXPAND registry ...

SAN DIEGO, CA (UPDATED)—It’s a shocking success for the MitraClip after years of gloomy predictions, sluggish trial enrollment, and—most of all—the negative MITRA-FR trial results last month. Today, ...

PARIS, France—New insights from the COAPT trial indicate that regardless of the treatment approach for patients with heart failure and severe secondary mitral regurgitation (MR), lower residual MR at ...